CN210

CN210 is a **quinazoline-based bromodomain and extra-terminal motif (BET) inhibitor** that also inhibits the bromodomains of the **histone acetyltransferases CREB-binding protein (CBP) and p300**. It acts by suppressing the expression of proinflammatory cytokines (including TNF-α, IL-6, IFN-γ, IL-17, IL-12α, and IL-23α) primarily through attenuation of the **NF-κB and mitogen-activated protein kinase (MAPK) pathways**, particularly affecting ERK and JNK phosphorylation[1][7]. CN210 was developed as a therapeutic candidate for **NSAID-induced ileitis** and broader applications in **inflammatory bowel disease (IBD), Crohn’s disease, and experimental arthritis**. It demonstrates oral bioavailability and dose-dependent efficacy in murine models[1][3][5][7].

Brand names

CN210CN-210CN 210

Other names

CN210CN-210CN 210